ANNEXON INC (ANNX)
US03589W1027 - Common Stock
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for...
Annexon Biosciences to Participate in Upcoming September Investor Conferences
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for...
ANNX Stock Earnings: Annexon Meets EPS for Q2 2024
ANNX stock results show that Annexon met analyst estimates for earnings per share the second quarter of 2024.
ANNX Stock Earnings: Annexon Meets EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Annexon (NASDAQ:ANNX) just reported results for the second quarter of 2024.Anne...
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phase 3 Trial; Potential to be First...
Commit To Purchase Annexon At $4, Earn 19.5% Annualized Using Options
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for...
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral...
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two...
7 Top Stocks Under $10: June 2024 Edition
While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
Annexon Announces Pricing of $125 Million Underwritten Public Offering
Annexon Announces Pricing of $125 Million Underwritten Public Offering
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of...
Annexon Announces Proposed Public Offering of Common Stock
Annexon Announces Proposed Public Offering of Common Stock
BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of...